论文部分内容阅读
目的 比较两种剂量的重组复合干扰素 (ConsensusInterferon ,CIFN)和重组干扰素α 2a(IFNα 2a)治疗慢性丙型肝炎患者的疗效和安全性。方法 187例初治的慢性丙型肝炎 (丙肝 )患者 ,随机分成三组 ,分别接受 :CIFN 15 μg(A组 ) 6 1例、9μg(B组 ) 6 5例和IFNα 2a 3MU(C组 ) 6 1例 ,1周 3次 ,共 2 4周 ,在完成治疗后继续随访 2 4周。本试验以治疗结束时和随访时丙氨酸转氨酶(ALT)复常和丙型肝炎病毒核糖核酸 (HCVRNA)逆转录 聚合酶链反应 (RT PCR)检查阴转考核药物近期和远期疗效 ,同时观察不良反应。结果 180例完成 2 4周治疗 ,分别为CIFN 15 μg组 5 6例 ,9μg组 6 3例和IFNα 2a组 6 1例。经 2 4周治疗后 ,A、B、C三组的ALT复常率分别为 76 .9%、6 8.3%和 5 7.4% ,HCVRNA的阴转率分别为 89.6 %、73.6 %和 6 0 .4% ,A组和C组比较差异均有显著性 (P<0 .0 5和P <0 .0 1)。在 48周时 ,A、B、C三组的ALT复常率分别为 78.8%、6 3.9%和 5 5 .0 % ,HCVRNA的阴转率分别为 75 .0 %、6 5 .4%和 5 4.7% ,A组和C组比较差异均有显著性 (P <0 .0 1和P<0 .0 5 )。三组患者近期显效率分别为 70 .8%、5 4.7%和 34 .0 % ;远期显效率分别为 6 4.6 %、5 1.9%和43.4%。A组的近期和远期疗效均显著高于C组 (P <0 .0 1和P
Objective To compare the efficacy and safety of two doses of recombinant interferon-alpha (CIFN) and recombinant interferon alpha 2a (IFNα 2a) in the treatment of chronic hepatitis C patients. Methods A total of 187 patients with newly diagnosed chronic hepatitis C (HCV) were randomly divided into three groups: 61 cases of CIFN 15 μg (group A), 65 cases of 9 μg (group B) and 3 mg IFNα 2a (group C) 61 cases, 3 times a week, a total of 2 4 weeks, after the completion of treatment were followed up for 24 weeks. This trial examined the short-term and long-term efficacy of over-the-counter medications with alanine aminotransferase (ALT) normalization and HCV RNA reverse transcription polymerase chain reaction (RT PCR) at the end of treatment and at follow-up Adverse reactions observed. Results 180 cases completed 24 weeks of treatment, which were 56 cases in the CIFN 15 μg group, 63 cases in the 9 μg group and 61 cases in the IFNα 2a group. The ALT abnormalities in groups A, B and C were 76.9%, 6.38% and 5.4% respectively after 24 weeks’ treatment. The negative conversion rates of HCVRNA were 89.6%, 73.6% and 60% respectively. 4%, there was significant difference between group A and group C (P <0.05 and P <0.01). At week 48, ALT normalization rates in groups A, B and C were 78.8%, 6 3.9% and 55.0%, respectively, and the negative conversion rates of HCV RNA were 75.0% and 65.4%, respectively 5 4.7%. There was significant difference between group A and group C (P <0.01 and P <0.05). The short-term effective rates of the three groups were 70.8%, 57.4% and 34.0% respectively, and the long-term effective rates were 6 4.6%, 5 1.9% and 43.4% respectively. The short-term and long-term effects of group A were significantly higher than those of group C (P <0.01 and P <